RT Journal Article
SR Electronic
T1 Humoral immune responses to COVID-19 vaccination in people living with HIV on suppressive antiretroviral therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.03.21264320
DO 10.1101/2021.10.03.21264320
A1 Brumme, Zabrina L.
A1 Mwimanzi, Francis
A1 Lapointe, Hope R.
A1 Cheung, Peter
A1 Sang, Yurou
A1 Duncan, Maggie C.
A1 Yaseen, Fatima
A1 Agafitei, Olga
A1 Ennis, Siobhan
A1 Ng, Kurtis
A1 Basra, Simran
A1 Lim, Li Yi
A1 Kalikawe, Rebecca
A1 Speckmaier, Sarah
A1 Moran-Garcia, Nadia
A1 Young, Landon
A1 Ali, Hesham
A1 Ganase, Bruce
A1 Umviligihozo, Gisele
A1 Omondi, F. Harrison
A1 Atkinson, Kieran
A1 Sudderuddin, Hanwei
A1 Toy, Junine
A1 Sereda, Paul
A1 Burns, Laura
A1 Costiniuk, Cecilia T.
A1 Cooper, Curtis
A1 Anis, Aslam H.
A1 Leung, Victor
A1 Holmes, Daniel
A1 DeMarco, Mari L.
A1 Simons, Janet
A1 Hedgcock, Malcolm
A1 Romney, Marc G.
A1 Barrios, Rolando
A1 Guillemi, Silvia
A1 Brumme, Chanson J.
A1 Pantophlet, Ralph
A1 Montaner, Julio S.G.
A1 Niikura, Masahiro
A1 Harris, Marianne
A1 Hull, Mark
A1 Brockman, Mark A.
YR 2021
UL http://medrxiv.org/content/early/2021/10/04/2021.10.03.21264320.abstract
AB Background Our understanding of COVID-19 vaccine immune responses in people living with HIV (PLWH) remains incomplete.Methods We measured circulating antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and ACE2 displacement activities after one and two COVID-19 vaccine doses in 100 adult PLWH and 152 controls.Results All PLWH were receiving suppressive antiretroviral therapy, with median CD4+ T-cell counts of 710 (IQR 525-935) cells/mm3. Median nadir CD4+ T-cell counts were 280 (IQR 120- 490) cells/mm3, and ranged as low as <10 cells/mm3. After adjustment for sociodemographic, health and vaccine-related variables, HIV infection was associated with 0.2 log10 lower anti-RBD antibody concentrations (p=0.03) and ∼7% lower ACE2 displacement activity (p=0.037) after one vaccine dose. Following two vaccine doses however, the association between HIV and weaker responses no longer remained. Rather, older age, a higher burden of chronic health conditions, and having received two ChAdOx1 doses (as opposed to a heterologous or dual mRNA vaccine regimen) were the most significant correlates of weaker humoral responses. No significant association was observed between the most recent or nadir CD4+ T-cell counts and responses to COVID-19 vaccination in PLWH following two vaccine doses.Conclusions These results suggest that PLWH whose viral loads are well-controlled on antiretroviral therapy and whose CD4+ T-cell counts are in a healthy range will generally not require a third COVID-19 vaccine dose as part of their initial immunization series, though other factors such as older age, co-morbidities, type of initial vaccine regimen and durability of vaccine responses will influence when this group may benefit from additional doses. Further studies of PLWH who are not receiving antiretroviral treatment and/or who have low CD4+ T-cell counts are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from Genome BC, the Michael Smith Foundation for Health Research, and the BCCDC Foundation for Public Health through a rapid SARS-CoV-2 vaccine research initiative in BC award (VAC-009 to MAB and ZLB). It was also supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 Award (to MAB, ZLB), the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (to CJB, MAB, MN, MLD, RP, ZLB), a British Columbia Ministry of Health/Providence Health Care Research Institute COVID-19 Research Priorities Grant (to CJB) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). LYL was supported by an SFU Undergraduate Research Award. GU and FHO are supported by Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # DEL 15 006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to the corresponding author. As per funder requirements, all data will also be deposited into a national database at the conclusion of the study.